About the Company
VeriStrat is a test developed to evaluate patient prognosis and, additionally, predict benefit from cancer treatment by EGFR inhibitors. It is a serum/plasma proteomic test developed using matrix-assisted laser desorption/ionization (MALDI) mass spectrometry. VeriStrat was developed by Biodesix, Inc., a molecular diagnostics company based in Boulder, Colorado, US. The VeriStrat algorithm has been interrogated retrospectively and prospectively in samples from randomized trials, such as the PROSE study, confirming the prognostic information associated with the molecular signature. In addition, the test appeared to be predictive of erlotinib impact on survival, as only "VeriStrat Good patients" benefited from such a treatment. Additional studies have confirmed its clinical relevance.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $BDSX News
Biodesix, Inc. (BDSX)
As of 11:17 AM EDT. Market Open. LOUISVILLE, Colo., October 07, 2024--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new ...
Biodesix, Inc. (NASDAQ:BDSX) Receives $3.08 Consensus Target Price from Analysts
Biodesix, Inc. (NASDAQ:BDSX – Get Free Report) has been assigned a consensus rating of “Buy” from the seven brokerages that are currently covering the firm, MarketBeat Ratings reports.
Biodesix Announces New Data Presentation at CHEST 2024 Annual Meeting and the Launch of a Complementary Clinical Study
Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data will be presented at the CHEST Annual Meeting 2024 in Boston ...
Biodesix to Present at Two Investor Conferences in September
Biodesix is a leading diagnostic solutions company with five Medicare-covered tests available for patients with lung diseases. The blood-based Nodify Lung® Nodule Risk Assessment, consisting of ...
Biodesix Inc Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Biodesix Announces New Data Presentation at CHEST 2024 Annual Meeting and the Launch of a Complementary Clinical Study
Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data will be presented at the CHEST Annual Meeting 2024 in Boston, ...
Biodesix Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Biodesix Announces New Data Presentation at CHEST 2024 Annual Meeting and the Launch of a Complementary Clinical Study
Analysis of 35,000 patients tested with Nodify Lung® Nodule Risk Assessment in a real-world setting to be presented at CHEST 2024 and launch of a new clinical study designed to expand data ...
Biodesix, Inc. (BDSX)
LOUISVILLE, Colo., September 05, 2024--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that members of the Biodesix management team ...
Biodesix Announces New Data Presentation at CHEST 2024 Annual Meeting and the Launch of a Complementary Clinical Study
Analysis of 35,000 patients tested with Nodify Lung® Nodule Risk Assessment in a real-world setting to be presented at CHEST 2024 and launch of a new clinical study designed to expand data ...
Loading the latest forecasts...